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ABSTRACT
Objective: To analyse the differential influence of risk
factors of peripheral artery disease (PAD) according to
age in patients with SLE.
Methods: 216 patients from the Lupus-Cruces cohort
were divided in three age groups: ≤34 years, 35–
49 years and ≥50 years. A low ankle–brachial index
defined PAD. Significant variables were identified by
univariant and multivariant analysis in each age group.
Results: Different factors were identified in different
age groups: antiphospholipid antibodies/
antiphospholipid syndrome and glucocorticoids in
patients ≤34 years; in patients 35–49 years old,
hypertension was the only statistically significant
predictor, although a trend was observed for fibrinogen
levels; a trend was observed for hypercholesterolaemia
in those ≥50 years.
Conclusions: Age may modulate the influence of risk
factors for PAD in patients with SLE.
INTRODUCTION
Cardiovascular disease (CVD) is the main
cause of late mortality in patients with SLE.1
The incidence of CVD has progressively
increased within the last decades.2 CVD can
present as coronary artery disease (CAD),
cerebrovascular disease and peripheral artery
disease (PAD), the ﬁrst two ones being best
studied.3 The underlying atherosclerotic
process can be accelerated by different
mechanisms, including inﬂammation, SLE
treatments and traditional cardiovascular risk
factors.3
Age is the most important unchangeable
cardiovascular risk factor, both in the general
population and in patients with lupus.4 5
Indeed, in a previous study in our SLE
cohort, age was the only independent pre-
dictor of PAD.6 In a nationwide population-
based cohort study in Taiwan, younger
(≤34 years) patients with SLE were at a
higher risk of symptomatic PAD.7 In a
Swedish population-based study, an increased
risk of myocardial infarction and stroke was
demonstrated among female patients with
SLE compared with the general population.
Of note, this extra risk was highest among
women aged 40–49 years.8
Thus, it is possible that the inﬂuence
of risk factors, either cardiovascular or
SLE-related, varies depending on the age
of patients. To test this hypothesis, we aimed
to study the inﬂuence of risk factors for PAD
in different age groups of patients with SLE.
MATERIALS AND METHODS
Study objectives
The objective of this cross-sectional study was
to analyse the differential inﬂuence, accord-
ing to age, of several variables in the pres-
ence of PAD, deﬁned as a low ankle–brachial
index (ABI). Patients were divided in three
groups according to age at the time of the
ABI, as proposed by Chuang et al:7 ≤34 years
(group 1), 35–49 years (group 2) and
≥50 years (group 3).
Study population
Data from the 216 patients who participated in
our previous study6 were further analysed.
Detailed characteristics of this population and
the variables studied are available.6 The local
institutional review board of the Hospital
Universitario Cruces approved the study proto-
col (CEIC E09/07) in compliance with the
Helsinki Declaration. All patients signed an
informed consent at the time of enrolment.
Statistical analysis and variables
In order to identify associations with PAD,
the following independent variables were
tested in each age group against the depend-
ent variable, ‘ABI lower than 0.9’, using χ2
with Yate’s correction or Student’s t-test, as
appropriate: age at SLE diagnosis, disease
duration, gender, abdominal obesity (≥102
and ≥88 in men and women, respectively),
metabolic syndrome according to Adult
Treatment Panel III deﬁnition,9 diabetes mel-
litus (DM), arterial hypertension (HTN), dys-
lipidaemia, smoking (current or past), any
vascular risk factor (DM or HTN or
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dyslipidaemia or current/past smoking), exercise,
alcohol consumption, family history of premature CVD,
body mass index, menopause, previous subclinical organ
damage (left ventricular hypertrophy and microalbumi-
nuria), previous CVD (ischaemic heart disease and/or
heart failure (IHD/HF), stroke, PAD), chronic renal
failure, previous arterial thrombosis (stroke or IHD or
PAD), uric acid, vitamin D levels, previous lupus neph-
ritis or antiphospholipid syndrome (APS), anti-DNA,
anti-Ro, anti-La, anti-U1RNP, anti-Sm, and antiphospho-
lipid antibodies (aPL) that include lupus anticoagulant
and/or anticardiolipin antibodies at medium–high levels
on at least two different determinations 12 weeks apart,
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) at the time of diagnosis, SLEDAI at the time
of ABI, SLICC/ACR Damage Index (SDI) at the time of
ABI, prednisone (cumulative dose, maximum dose ever
received, average daily dose <7.5 or ≥7.5), hydroxichlor-
oquine (yes/no and cumulative dose), cyclophospha-
mide (cumulative dose), mycophenolate (cumulative
dose), azathioprine (cumulative dose), low-dose aspirin
(number of months on treatment), anticoagulants
(number of months on treatment), statins (number of
months on treatment) and ﬁbrinogen levels at the time
of the ABI.
Those variables with a value of p ≤0.1 in the univariate
analysis were subsequently included in a backward step-
wise logistic regression model to identify independent
associations with PAD for each age subgroup.
All statistical analyses were done using the
software SPSS V.20.0 statistical package for MAC OS X
(SPSS).
RESULTS
Demographic and SLE-related variables
Two hundred patients (92%) were women. Two
hundred and nine patients (96%) were Caucasians of
European origin, with the remaining consisting of three
Afro-Caribbeans, two Hispanics and two Arabs. The
mean (SD) age at SLE diagnosis was 36 years (15). The
mean (SD) age at the time of the ABI study was 49 (15)
years, with a mean (SD) follow-up after SLE diagnosis of
12 (9) years.
A total of 37 patients were included in group 1, 84
patients in group 2 and 95 patients in group 3. The dis-
tribution of traditional cardiovascular risk factors and
SLE-related factors in the three age groups is detailed in
table 1.
Frequency and associations of low ABI
The prevalence of PAD increased with age: 3/37 (8.1%)
in group 1, 12/84 (14.2%) in group 2 and 31/95
(32.6%) in group 3. The variables associated with PAD
in each age group are shown in table 2: APS, aPL and
cumulative prednisone dose in group 1; DM, hyperten-
sion, average daily dose of prednisone <7.5 mg/day,
abdominal obesity and ﬁbrinogen levels in group 2; and
vitamin D levels, hypercholesterolaemia, any vascular
risk factor (DM or hypertension or hypercholesterol-
aemia or current/past smoking), ischaemic heart
disease, aPL, previous arterial thrombosis, cumulative
mycophenolote mofetil dose and average daily dose of
prednisone <7.5 in group 3.
The ﬁnal independent predictors of low ABI are
shown in table 3. In group 1, the logistic regression
Table 1 Traditional and SLE-related cardiovascular risk factors in different age groups
Group 1 (≤34 years) Group 2 (35–49 years) Group 3 (≥50 years)
HTN, n/N (%) 4/37 (10.8) 20/84 (23.8) 47/95 (49.4)
DM, n/N (%) 0/37 (0) 3/84 (3.5) 4/95 (4.2)
DLP, n/N (%) 3/37 (8.1) 20/84 (23.8) 51/95 (53.6)
Current smoker, n/N (%) 15/37 (40.5) 28/84 (33.3) 22/95 (23.1)
Smoker (ever), n/N (%) 18/37 (48.6) 49/84 (58.3) 41/95 (43.1)
Family history, n/N (%) 2/37 (5.4) 10/84 (11.9) 13/95 (13.6)
Abdominal obesity, n/N (%) 10/37 (27) 25/84 (29.7) 38/95 (40)
BMI, n/N (%) overweight–obesity 13/37 (35.1) 44/84 (52.3) 52/95 (54.7)
Sedentary lifestyle, n/N (%) 20/37 (54) 35/84 (41.6) 42/95 (44.2)
Any vascular risk factor, n/N (%) 22/37 (59.4) 59/84 (70.2) 80/95 (84.2)
MS, n/N (%) 3/37 (8.1) 6/84 (7.1) 12/95 (12.6)
APS, n/N (%) 2/37 (5.4) 10/84 (11.9) 9/95 (9.4)
aPL, n/N (%) 14/37 (29.7) 27/84 (32.1) 33/95 (34.7)
Lupus nephritis, n/N (%) 12/37 (32.4) 30/84 (35.7) 18/95 (18.9)
SLEDAI at dx, mean (SD) 9.83 (7.8) 8.15 (5.3) 6.1 (3.9)
SLEDAI at ABI, mean (SD) 3.08 (3.7) 2.05 (2.9) 1.5 (2.2)
SDI at ABI, mean (SD) 0.4 (0.8) 0.98 (1.2) 1.5 (1.5)
Age at SLE dx, years, mean (SD) 21.4 (6.1) 30.2 (9.2) 47.4 (15.6)
Disease duration, years, mean (SD) 6.2 (5.3) 11.7 (8.5) 15 (10.5)
Any vascular risk factor: DLP, hypercholesterolaemia; HTN, DM, dyslipidaemia or smoking exposed. ABI, ankle–brachial index;
aPL, antiphospholipid antibodies (anticardiolipin and/or lupus anticoagulant); APS, antiphospholipid syndrome; BMI, body mass index;
DM, diabetes mellitus; dx, diagnosis; HTN, arterial hypertension; MS, metabolic syndrome according to ATPIII.
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model could not be built due to the absolute absence of
any patients with APS in the subgroup with normal ABI
and the 100% frequency of aPL positivity among those
with abnormal ABI; thus, the results of the univariate
analysis could not be adjusted. In group 2, hypertension
was the only statistically signiﬁcant predictor, although a
trend was observed for ﬁbrinogen levels. In group 3, a
trend was observed for hypercholesterolaemia.
DISCUSSION
Age is among the most important cardiovascular risk
factors; indeed, many of the cardiovascular risk estimation
models are actually based on age.4 5 In a cohort of more
than 3.6 million individuals undergoing self-referred
screening for CVD (ABI, carotid duplex ultrasound and
abdominal ultrasound), the prevalence of any vascular
disease increased progressively after 40 years of age: from
2% in those aged 40–50 years to 13% among those aged
71–80 years. After adjusting for traditional risk factors,
each additional decade of life doubled the risk for vascular
disease (OR 2.14 for PAD).10
Moreover, the differential inﬂuence of cardiovascular
risk factors changes throughout life. In the general popu-
lation, the Framingham study found that the relative
effect of systolic, diastolic and pulse pressure changed
with age. In patients younger than 50 years, diastolic
blood pressure was the strongest predictor of coronary
heart disease (CHD) risk; in those aged 50–59 years old,
all three variables contributed equally to CHD risk;
among those older than 60 years, pulse pressure was the
strongest predictor.11
Our results suggest that age may modulate the effect
of risk factors for CVD also in patients with SLE. aPL/
APS and higher glucocorticoid load seem to increase
the risk of PAD in younger patients, although a multivar-
iant analysis could not be performed. In group 2, an
average daily dose of prednisone <7.5 mg was associated
with PAD in the univariate but not in the multivariate
analysis. Moreover, since more than 75% of patients in
this age group were taking low-dose prednisone, this
result is likely to be misleading. As age increased, more
traditional risk factors such as hypertension and hyper-
cholesterolaemia played a signiﬁcant role. We identiﬁed
factors associated with PAD (and, probably, by extension
with CVD) hidden by the large inﬂuence of age. This
could be particularly important among younger patients,
in whom the prevalence of arterial disease was low,
however very much unrelated to classical cardiovascular
risk factors.
Table 2 Univariate analysis showing variables with p<0.1
Low ABI Normal ABI p Value
Group 1 (≤34 years) N=3 N=34
APS, n/N (%) 2/3 (66) 0/34 (0) 0.005
aPL, n/N (%) 3/3 (100) 11/34 (32.3) 0.047
Cumulative prednisone, g, mean (SD) 21.25 (1.89) 7.70 (1.08) 0.058
Group 2 (35–49 years) N=12 N=72
DM, n/N (%) 2/12 (16.6) 1/72 (1.3) 0.052
HTN, n/N (%) 6/12 (50) 14/72 (19.4) 0.021
Average prednisone <7.5 mg/day, n/N (%) 11/11 (100) 50/68 (73.5) 0.046
Abdominal obesity, cm, mean (SD) 90.46 (14.9) 82.50 (12.2) 0.047
Fibrinogen levels, mg/dL, mean (SD) 454 (100) 388 (83.2) 0.021
Group 3 (≥50 years) N=31 N=64
Vitamin D levels, ng/mL, mean (SD) 22.2 (8.7) 35.9 (41.4) 0.018
Hypercholesterolaemia, n/N (%) 21/31 (67.7) 30/64 (46.8) 0.056
Any vascular risk factor (ever smoking), n/N (%) 30/31 (96.7) 50/64 (78.1) 0.015
Any vascular risk factor (current smoking), n/N (%) 28/31 (90.3) 44/64 (68.7) 0.023
Ischaemic heart disease, n/N (%) 4/31 (12.9) 2/64 (3.1) 0.086
aCL, n/N (%) 4/31 (12.9) 24/64 (37.5) 0.011
aPL, n/N (%) 6/31 (19.3) 27/64 (42.1) 0.028
Arterial thrombosis, n/N (%) 11/31 (35.4) 11/64 (17.1) 0.047
Cumulative MMF, g, mean (SD) 0 (0) 111 (442.8) 0.049
Average prednisone <7.5 mg/day, n/N (%) 28/30 (93.3) 48/63 (76.1) 0.038
ABI, ankle–brachial index; aCL, anticardiolipin antibodies; aPL, antiphospholipid antibodies (anticardiolipin and/or lupus anticoagulant); APS,
antiphospholipid syndrome; DM, diabetes mellitus; HTN, arterial hypertension; MMF, mycophenolote mofetil.
Table 3 Variables associated with a low ABI in different
age groups (multivariate analysis)
Variables OR 95% CI p Value
Group 1
N/A
Group 2
Hypertension 4.61 1.15 to 18.44 0.031
Group 3
Hypercholesterolaemia 2.49 0.97 to 6.4 0.057
ABI, ankle–brachial index; N/A, not applicable.
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This study has a number of limitations, which have
been already acknowledged.6 This is a cross-sectional
study, with different disease duration among patients.
This makes it difﬁcult to fully address the effects of
some time-varying variables such as glucocorticoid
exposure, lupus activity and cardiovascular risk factors.
In addition, almost 90% of our cohort was on hydroxy-
chloroquine, which precludes analysis of the actual
effect of this drug. On the other hand, the sizeable
number of patients has allowed a differential analysis
per different age groups using a large variety of demo-
graphic, cardiovascular, lupus-related and therapeutic
variables. This is, to our knowledge, the ﬁrst study of this
kind.
Based on our results, a number of practical considera-
tions can be made. First, it is important to regularly
check patients with lupus for the presence of aPL, espe-
cially in the early phases of the disease, given the pos-
sible association with PAD in young patients with SLE.
We have previously shown that aPL increase the risk of
damage in SLE,12 particularly by the occurrence of
thrombotic events.13 Since the addition of low-dose
aspirin seems to be protective in aPL-positive patients
with SLE according to a recent systematic review,14 the
detection of persistently positive aPL should call for
early antiplatelet therapy. Second, the doses of prednis-
one should be reduced as much as possible, especially
in young patients, given the possible association with
PAD in this group and, in general, with damage in
patients with SLE.15 Third, especial attention should be
paid to controlling traditional cardiovascular risk factors,
especially in older patients.
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